FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Clinical and economic outcomes of new oral anticoagulants in orthopaedics

Klinički i ekonomski ishodi primene novih oralnih antikoagulanasa u ortopediji

Thumbnail
2018
3028.pdf (216.8Kb)
Authors
Lakić, Dragana
Travica, Jovana
Odalović, Marina
Tadić, Ivana
Article (Published version)
Metadata
Show full item record
Abstract
Venous thromboembolism, including pulmonary embolism and deep vein thrombosis, is a signifi cant factor in morbidity and mortality of patients. New oral anticoagulants, such as apixaban, dabigatran, and rivaroxaban, have recently demonstrated their safety and efficacy in patients undergoing major orthopaedic surgery. Selection of the appropriate drug should be adjusted according to patient needs. Major bleeding is rare with new oral anticoagulants and is comparable with the bleeding rate associated with low-molecular-weight heparins. Clinical data indicate that therapy with apixaban and rivaroxaban was more effective compared to enoxaparin, while dabigatran has a similar efficacy to enoxaparin. Cost-effectiveness studies of new oral anticoagulants showed that these medicines offer higher efficacy with acceptable costs for the healthcare system, even saving costs in certain cases. Clinical practice in Serbia reflects considerably more frequent use of traditional anticoagulant medication... therapy compared to new oral anticoagulants.

Venska tromboembolija, koja uključuje plućnu emboliju i duboku vensku trombozu, predstavlja značajan faktor morbiditeta i mortaliteta pacijenata. Novi oralni antikoagulansi, poput apiksabana, dabigatrana i rivaroksabana, su nedavno pokazali svoju bezbednost i efikasnost kod pacijenata koji se podvrgavaju velikim ortopedskim intervencijama. Izbor odgovarajućeg leka treba prilagoditi individualnim potrebama pacijenta. Velika krvarenja su relativno retka u toku primene novih oralnih antikoagulanasa i uporedivi su sa stopom krvarenja prilikom primene nisko-molekularnih heparina. Klinički podaci ukazuju da je terapija apiksabanom i rivarokabanom efikasnija u odnosu na enoksaparin, dok dabigatran ima slične efekte kao enoksaparin. Troškovna isplativost novih oralnih antikoagulanasa potvrđuje veću efikasnost sa prihvatljivim troškovima za zdravstveni sistem, u nekim slučajevima čak i sa uštedama.
Keywords:
new oral anticoagulant / orthopaedic surgery / clinical outcomes / economic outcomes / novi oralni antikoagulansi / ortopedska hirurgija / klinički ishodi / ekonomski ishodi
Source:
Serbian Journal of Experimental and Clinical Research, 2018, 19, 1, 3-9
Publisher:
  • Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac
Funding / projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)
  • The interaction of xenobiotics with biological systems (RS-41012)

DOI: 10.1515/SJECR-2017-0066

ISSN: 1820-8665

Scopus: 2-s2.0-85044787524
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3030
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Lakić, Dragana
AU  - Travica, Jovana
AU  - Odalović, Marina
AU  - Tadić, Ivana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3030
AB  - Venous thromboembolism, including pulmonary embolism and deep vein thrombosis, is a signifi cant factor in morbidity and mortality of patients. New oral anticoagulants, such as apixaban, dabigatran, and rivaroxaban, have recently demonstrated their safety and efficacy in patients undergoing major orthopaedic surgery. Selection of the appropriate drug should be adjusted according to patient needs. Major bleeding is rare with new oral anticoagulants and is comparable with the bleeding rate associated with low-molecular-weight heparins. Clinical data indicate that therapy with apixaban and rivaroxaban was more effective compared to enoxaparin, while dabigatran has a similar efficacy to enoxaparin. Cost-effectiveness studies of new oral anticoagulants showed that these medicines offer higher efficacy with acceptable costs for the healthcare system, even saving costs in certain cases. Clinical practice in Serbia reflects considerably more frequent use of traditional anticoagulant medication therapy compared to new oral anticoagulants.
AB  - Venska tromboembolija, koja uključuje plućnu emboliju i duboku vensku trombozu, predstavlja značajan faktor morbiditeta i mortaliteta pacijenata. Novi oralni antikoagulansi, poput apiksabana, dabigatrana i rivaroksabana, su nedavno pokazali svoju bezbednost i efikasnost kod pacijenata koji se podvrgavaju velikim ortopedskim intervencijama. Izbor odgovarajućeg leka treba prilagoditi individualnim potrebama pacijenta. Velika krvarenja su relativno retka u toku primene novih oralnih antikoagulanasa i uporedivi su sa stopom krvarenja prilikom primene nisko-molekularnih heparina. Klinički podaci ukazuju da je terapija apiksabanom i rivarokabanom efikasnija u odnosu na enoksaparin, dok dabigatran ima slične efekte kao enoksaparin. Troškovna isplativost novih oralnih antikoagulanasa potvrđuje veću efikasnost sa prihvatljivim troškovima za zdravstveni sistem, u nekim slučajevima čak i sa uštedama.
PB  - Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac
T2  - Serbian Journal of Experimental and Clinical Research
T1  - Clinical and economic outcomes of new oral anticoagulants in orthopaedics
T1  - Klinički i ekonomski ishodi primene novih oralnih antikoagulanasa u ortopediji
VL  - 19
IS  - 1
SP  - 3
EP  - 9
DO  - 10.1515/SJECR-2017-0066
ER  - 
@article{
author = "Lakić, Dragana and Travica, Jovana and Odalović, Marina and Tadić, Ivana",
year = "2018",
abstract = "Venous thromboembolism, including pulmonary embolism and deep vein thrombosis, is a signifi cant factor in morbidity and mortality of patients. New oral anticoagulants, such as apixaban, dabigatran, and rivaroxaban, have recently demonstrated their safety and efficacy in patients undergoing major orthopaedic surgery. Selection of the appropriate drug should be adjusted according to patient needs. Major bleeding is rare with new oral anticoagulants and is comparable with the bleeding rate associated with low-molecular-weight heparins. Clinical data indicate that therapy with apixaban and rivaroxaban was more effective compared to enoxaparin, while dabigatran has a similar efficacy to enoxaparin. Cost-effectiveness studies of new oral anticoagulants showed that these medicines offer higher efficacy with acceptable costs for the healthcare system, even saving costs in certain cases. Clinical practice in Serbia reflects considerably more frequent use of traditional anticoagulant medication therapy compared to new oral anticoagulants., Venska tromboembolija, koja uključuje plućnu emboliju i duboku vensku trombozu, predstavlja značajan faktor morbiditeta i mortaliteta pacijenata. Novi oralni antikoagulansi, poput apiksabana, dabigatrana i rivaroksabana, su nedavno pokazali svoju bezbednost i efikasnost kod pacijenata koji se podvrgavaju velikim ortopedskim intervencijama. Izbor odgovarajućeg leka treba prilagoditi individualnim potrebama pacijenta. Velika krvarenja su relativno retka u toku primene novih oralnih antikoagulanasa i uporedivi su sa stopom krvarenja prilikom primene nisko-molekularnih heparina. Klinički podaci ukazuju da je terapija apiksabanom i rivarokabanom efikasnija u odnosu na enoksaparin, dok dabigatran ima slične efekte kao enoksaparin. Troškovna isplativost novih oralnih antikoagulanasa potvrđuje veću efikasnost sa prihvatljivim troškovima za zdravstveni sistem, u nekim slučajevima čak i sa uštedama.",
publisher = "Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac",
journal = "Serbian Journal of Experimental and Clinical Research",
title = "Clinical and economic outcomes of new oral anticoagulants in orthopaedics, Klinički i ekonomski ishodi primene novih oralnih antikoagulanasa u ortopediji",
volume = "19",
number = "1",
pages = "3-9",
doi = "10.1515/SJECR-2017-0066"
}
Lakić, D., Travica, J., Odalović, M.,& Tadić, I.. (2018). Clinical and economic outcomes of new oral anticoagulants in orthopaedics. in Serbian Journal of Experimental and Clinical Research
Univerzitet u Kragujevcu - Fakultet medicinskih nauka, Kragujevac., 19(1), 3-9.
https://doi.org/10.1515/SJECR-2017-0066
Lakić D, Travica J, Odalović M, Tadić I. Clinical and economic outcomes of new oral anticoagulants in orthopaedics. in Serbian Journal of Experimental and Clinical Research. 2018;19(1):3-9.
doi:10.1515/SJECR-2017-0066 .
Lakić, Dragana, Travica, Jovana, Odalović, Marina, Tadić, Ivana, "Clinical and economic outcomes of new oral anticoagulants in orthopaedics" in Serbian Journal of Experimental and Clinical Research, 19, no. 1 (2018):3-9,
https://doi.org/10.1515/SJECR-2017-0066 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB